Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Bayer AG
  6. News
  7. Summary
    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bayer : says glyphosate settlement talks delayed by coronavirus - Handelsblatt

04/02/2020 | 05:09am EDT
FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen

Talks between Bayer AG and plaintiff lawyers to settle claims that the German company's glyphosate-based weedkillers cause cancer have been slowed by the coronavirus pandemic, Bayer's Chief Executive told daily Handelsblatt.

"This is about currently not being able to meet in person for talks. All this of course slows down the negotiations," CEO Werner Baumann told the newspaper in an interview published on Thursday.

Court-appointed mediator Ken Feinberg told Reuters last month that the talks were slowed by the pandemic.

In the Handelsblatt interview, CEO Baumann reiterated remarks he made at the end of February that he was under no time pressure to strike a settlement deal and that he would not submit to a schedule or deadline.

(Reporting by Ludwig Burger and Patricia Weiss; Editing by Michelle Martin)


ę Reuters 2020
All news about BAYER AG
06/11EXCLUSIVE : ECB tells Deutsche Bank to find new chairman fast - sources
RE
06/11MARKET CHATTER : Deutsche Bank Facing Increasing Pressure From ECB to Name Chair..
MT
06/10Mexico stalling GMO corn permits ahead of ban, says top farm lobby
RE
06/10Mexico stalling GMO corn permits ahead of ban, says top farm lobby
RE
06/10PRESS RELEASE : Tele Columbus AG: PYUR Business data centre in Leipzig successfu..
DJ
06/10DGAP-PVR : Bayer Aktiengesellschaft: Release -2-
DJ
06/10BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
EQ
06/10PRESS RELEASE : Pfizer and BioNTech to Provide 500 -3-
DJ
06/09GSK consumer arm confident that growth, cash flow will help with debt
RE
06/09BAYERá : BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase ..
AQ
More news
Financials
Sales 2021 41 349 M 50 065 M 50 065 M
Net income 2021 3 593 M 4 351 M 4 351 M
Net Debt 2021 38 658 M 46 807 M 46 807 M
P/E ratio 2021 15,7x
Yield 2021 3,79%
Capitalization 52 530 M 63 542 M 63 604 M
EV / Sales 2021 2,21x
EV / Sales 2022 2,08x
Nbr of Employees 99 329
Free-Float 100,0%
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 64,63 €
Last Close Price 53,47 €
Spread / Highest target 59,0%
Spread / Average Target 20,9%
Spread / Lowest Target -51,4%
EPS Revisions
Managers and Directors
NameTitle
Werner Baumann Chairman-Management Board
Wolfgang U. Nickl Chief Financial Officer
Norbert Winkeljohann Chairman-Supervisory Board
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG11.04%63 542
JOHNSON & JOHNSON4.82%434 405
ROCHE HOLDING AG10.68%328 612
PFIZER, INC.9.07%224 747
NOVARTIS AG-0.39%208 035
ABBVIE INC.7.72%203 857